Fluzone Trivalent Northern Hemisphere Injection, Suspension
NDC 49281-643
Product Information
Fluzone Trivalent Northern Hemisphere (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (formaldehyde inactivated), influenza a virus a/croatia/10136/rv/2023 (h3n2) antigen (formaldehyde inactivated), and influenza b virus b/michigan/01/2021 antigen (formaldehyde inactivated)) is a BLA-approved product labeled by Sanofi Vaccines Us Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection, suspension for intramuscular administration. This product entry covers the primary NDC 49281-643 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 49281-643?
What are the uses of this product?
What are Active Ingredients of this product?
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2709231 - influenza virus vaccine 2025 (trivalent - Croatia/Victoria/Michigan) Injectable Suspension
- RxCUI: 2709231 - influenza A virus A/Croatia/10136RV/2023 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/4897/2022 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML Injectable Suspension
- RxCUI: 2709236 - influenza virus vaccine 2025 (trivalent - Croatia/Victoria/Michigan) 0.5 mL Prefilled Syringe
- RxCUI: 2709236 - 0.5 ML influenza A virus A/Croatia/10136RV/2023 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/4897/2022 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML Prefilled Syringe
- RxCUI: 2719212 - Fluzone 2025-2026 vaccine 0.5 ML Prefilled Syringe
* Please review the full disclaimer at the bottom of this page.